JEAN FRANCOIS FORMELA
CIK 1030575 · last filed 2026-07-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$12.40M
Companies
10
Total Filings
58
Lifetime Open-Market Net
-$229.01M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KRRO | Director | 706,556 | $13.25 | $9.36M | -$4.04M | 7 | 2026-07-07 |
| ImageneBio, Inc. (IKNA) Delisted | Director | 241,801 | $17.16 | $4.15M | $1.61M | 6 | 2024-06-10 |
| NTLA | Director | 45,416 | $11.94 | $542.3K | -$155.43M | 20 | 2022-06-16 |
| Translate Bio, Inc. (TBIO) Delisted | Director | 0 | $0.00 | $0 | -$82.92M | 7 | 2021-09-14 |
| SPRO | Director | 1,979,557 | $1.26 | $2.49M | $6.00M | 6 | 2021-08-18 |
| Zyla Life Sciences (EGLT) Delisted | Director | 1,696,852 | — | — | $500.0K | 1 | 2014-02-12 |
| Oruka Therapeutics, Inc. (ABIO) Delisted | Director | 174 | $28.80 | $5.0K | -$1.06M | 5 | 2012-10-24 |
| Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Director | 3,688,294 | $116.30 | $428.95M | $6.33M | 2 | 2012-03-06 |
| ACHILLION PHARMACEUTICALS INC (TPTX) Delisted | Director | — | $76.01 | — | $0 | 1 | 2007-12-18 |
| SGX PHARMACEUTICALS, INC. (SGXP) Delisted | Director | — | — | — | $0 | 2 | 2007-07-18 |
Recent Filings · Page 5 of 6
58 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-03-22 | NTLA | Sell (S) | −39,245 | -$936.7K | EDGAR |
| 2017-11-07 | SPRO | Mixed | +2,365,347 | $6.00M | EDGAR |
| 2017-07-11 | NTLA | Sell (S) | −150,000 | -$2.44M | EDGAR |
| 2017-05-19 | NTLA | Grant (A) | — | $0 | EDGAR |
| 2017-03-13 | NTLA | Sell (S) | −21,132 | -$293.8K | EDGAR |
| 2016-05-11 | NTLA | Conv (C) | +4,429,788 | $0 | EDGAR |
| 2016-05-09 | NTLA | Grant (A) | — | $0 | EDGAR |
| 2014-02-12 | Zyla Life Sciences (EGLT) Delisted | Mixed | +2,152,222 | $2.80M | EDGAR |
| 2012-10-24 | Oruka Therapeutics, Inc. (ABIO) Delisted | Grant (A) | +317,379 | $125.0K | EDGAR |
| 2012-03-06 | Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Buy (P) | +828,443 | $3.00M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.